Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Cyrus Harmon of Olema Pharmaceuticals sold shares of common stock on February 29, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Cyrus Harmon, a director at Olema Pharmaceuticals, sold 24,900 shares of common stock at a weighted average price of $12.41 on February 29, 2024.
- An additional 100 shares were sold at a weighted average price of $13.00 on the same day.
- These sales were executed under a 10b5-1 trading plan adopted on May 16, 2023.
- Following these transactions, Harmon directly owns 846,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.
- The reporting person is the manager of Harmon Family Investors LLC.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing regarding stock sales by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives and directors to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sale may have a minor impact on shareholder sentiment, but is unlikely to be significant given the pre-planned nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| May 16, 2023 | Date of adoption of the 10b5-1 trading plan. |
| February 29, 2024 | Date of the reported stock sales. |
| March 04, 2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.